Advertisement

Efficacy and Safety of a Routine Early Invasive Strategy in Relation to Time from Symptom Onset to Fibrinolysis (a Subgroup Analysis of TRANSFER-AMI)

Published:January 31, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.01.533
      The aim of this study was to assess the efficacy and safety of an early invasive strategy post-fibrinolysis in relation to time from symptom onset to fibrinolysis in patients with ST-elevation myocardial infarction (STEMI). The Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) randomized 1,059 patients receiving fibrinolysis for STEMI to an early invasive strategy versus standard therapy. The primary end point was the composite of death, reinfarction, recurrent ischemia, new or worsening heart failure, or cardiogenic shock at 30 days. In this post hoc subgroup analysis, we examined the effect of an early invasive strategy on efficacy and safety outcomes after stratification by time from symptom onset to fibrinolysis (<2 or ≥2 hours). Of 1,059 patients in TRANSFER-AMI, 557 (53%) received fibrinolysis <2 hours and 502 (47%) ≥2 hours after symptom onset. Compared to patients who received fibrinolysis within 2 hours of symptoms, patients who received fibrinolysis ≥2 hours after symptom onset had higher Global Registry of Acute Coronary Events risk scores (median 127 vs 122, p = 0.004). The effect of an early invasive strategy did not differ between symptom-to-fibrinolysis time strata for the primary efficacy end point (p-heterogeneity = 0.67), 30-day mortality, the composite of death or reinfarction at 30 days, 6 months, or 1 year, or bleeding (all p-heterogeneity >0.40). In conclusion, the efficacy and safety of an early invasive strategy in patients undergoing fibrinolysis for STEMI do not vary in relation to time (<2 or ≥2 hours) from symptom onset to fibrinolysis.
      To read this article in full you will need to make a payment

      References

        • Cantor W.J.
        • Fitchett D.
        • Borgundvaag B.
        • Ducas J.
        • Heffernan M.
        • Cohen E.A.
        • Morrison L.J.
        • Langer A.
        • Dzavik V.
        • Mehta S.R.
        • Lazzam C.
        • Schwartz B.
        • Casanova A.
        • Goodman S.G.
        • for the TRANSFER-AMI Trial Investigators
        Routine early angioplasty after fibrinolysis for acute myocardial infarction.
        N Engl J Med. 2009; 360: 2705-2718
        • Cantor W.J.
        • Fitchett D.
        • Borgundvaag B.
        • Heffernan M.
        • Cohen E.A.
        • Morrison L.J.
        • Ducas J.
        • Langer A.
        • Mehta S.
        • Lazzam C.
        • Schwartz B.
        • Dzavik V.
        • Goodman S.G.
        Rationale and design of the trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (TRANSFER-AMI).
        Am Heart J. 2008; 155 ([Erratum appears in Am Heart J 2008;155(2):323 note: Ducas, John [added]]): 19-25
      1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.
        Lancet. 1994; 343: 311-322
        • Boersma E.
        • Maas A.C.
        • Deckers J.W.
        • Simoons M.L.
        Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour.
        Lancet. 1996; 348: 771-775
        • Steg P.G.
        • Bonnefoy E.
        • Chabaud S.
        • Lapostolle F.
        • Dubien P.-Y.
        • Cristofini P.
        • Leizorovicz A.
        • Touboul P.
        • Comparison of Angioplasty and Prehospital Thrombolysis In Acute Myocardial infarction (CAPTIM) Investigators
        Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
        Circulation. 2003; 108: 2851-2856
        • Westerhout C.M.
        • Bonnefoy E.
        • Welsh R.C.
        • Steg P.G.
        • Boutitie F.
        • Armstrong P.W.
        The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST.
        Am Heart J. 2011; 161: 283-290
        • Bovill E.G.
        • Terrin M.L.
        • Stump D.C.
        • Berke A.D.
        • Frederick M.
        • Collen D.
        • Feit F.
        • Gore J.M.
        • Hillis L.D.
        • Lambrew C.T.
        • Leiboff R.
        • Mann K.G.
        • Markis J.E.
        • Pratt C.M.
        • Sharkey S.W.
        • Sopko G.
        • Tracy R.P.
        • Chesebro J.H.
        Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), phase II trial.
        Ann Intern Med. 1991; 115: 256-265
      2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators.
        N Engl J Med. 1993; 329: 673-682
        • Granger C.B.
        • Goldberg R.J.
        • Dabbous O.
        • Pieper K.S.
        • Eagle K.A.
        • Cannon C.P.
        • Van De Werf F.
        • Avezum A.
        • Goodman S.G.
        • Flather M.D.
        • Fox K.A.A.
        • Global Registry of Acute Coronary Events Investigators
        Predictors of hospital mortality in the global registry of acute coronary events.
        Arch Intern Med. 2003; 163: 2345-2353
        • Yan A.T.
        • Yan R.T.
        • Cantor W.J.
        • Borgundvaag B.
        • Cohen E.A.
        • Fitchett D.H.
        • Dzavik V.
        • Ducas J.
        • Tan M.
        • Casanova A.
        • Goodman S.G.
        • TRANSFER-AMI Investigators
        Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
        Eur Heart J. 2011; 32: 1994-2002
        • Boersma E.
        • The Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 Trialists' Collaborative Group
        Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients.
        Eur Heart J. 2006; 27: 779-788
        • De Luca G.
        • Suryapranata H.
        • Ottervanger J.P.
        • Antman E.M.
        Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts.
        Circulation. 2004; 109: 1223-1225
        • De Luca G.
        • Suryapranata H.
        • Zijlstra F.
        • van 't Hof A.W.J.
        • Hoorntje J.C.A.
        • Gosselink A.T.M.
        • Dambrink J.H.
        • de Boer M.J.
        • ZWOLLE Myocardial Infarction Study Group
        Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty.
        J Am Coll Cardiol. 2003; 42: 991-997
        • Cantor W.J.
        • Brunet F.
        • Ziegler C.P.
        • Kiss A.
        • Morrison L.J.
        Immediate angioplasty after thrombolysis: a systematic review.
        CMAJ. 2005; 173: 1473-1481
        • Simoons M.L.
        • Arnold A.E.
        • Betriu A.
        • de Bono D.P.
        • Col J.
        • Dougherty F.C.
        • von Essen R.
        • Lambertz H.
        • Lubsen J.
        • Meier B.
        • Raynaud P.
        • Sanz G.A.
        • Serruys P.W.
        • Uebis R.
        • Van De Werf F.
        • Wood D.
        • Verstraete M.
        • European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator (rTPA)
        Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
        Lancet. 1988; 1: 197-203
        • Fitzgerald D.J.
        • Catella F.
        • Roy L.
        • FitzGerald G.A.
        Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
        Circulation. 1988; 77: 142-150
        • Coulter S.A.
        • Cannon C.P.
        • Ault K.A.
        • Antman E.M.
        • Van de Werf F.
        • Adgey A.A.
        • Gibson C.M.
        • Giugliano R.P.
        • Mascelli M.A.
        • Scherer J.
        • Barnathan E.S.
        • Braunwald E.
        • Kleiman N.S.
        High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14.
        Circulation. 2000; 101: 2690-2695
        • Rasmanis G.
        • Vesterqvist O.
        • Green K.
        • Edhag O.
        • Henriksson P.
        Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction.
        Br Heart J. 1992; 68: 374-376
        • Gurbel P.A.
        • Serebruany V.L.
        • Shustov A.R.
        • Bahr R.D.
        • Carpo C.
        • Ohman E.M.
        • Topol E.J.
        Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
        J Am Coll Cardiol. 1998; 31: 1466-1473
        • Keeley E.C.
        • Boura J.A.
        • Grines C.L.
        Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.
        Lancet. 2003; 361: 13-20
      3. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators.
        N Engl J Med. 1997; 336 ([Erratum appears in N Engl J Med 1997; 337(4):287]): 1621-1628
        • Andersen H.R.
        • Nielsen T.T.
        • Rasmussen K.
        • Thuesen L.
        • Kelbaek H.
        • Thayssen P.
        • Abildgaard U.
        • Pedersen F.
        • Madsen J.K.
        • Grande P.
        • Villadsen A.B.
        • Krusell L.R.
        • Haghfelt T.
        • Lomholt P.
        • Husted S.E.
        • Vigholt E.
        • Kjaergard H.K.
        • Mortensen L.S.
        • for the DANAMI-2 Investigators
        A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.
        N Engl J Med. 2003; 349: 733-742
        • Grines C.L.
        • Browne K.F.
        • Marco J.
        • Rothbaum D.
        • Stone G.W.
        • O'Keefe J.
        • Overlie P.
        • Donohue B.
        • Chelliah N.
        • Timmis G.C.
        • Vlietstra R.E.
        • Strzelecki M.
        • Puchrowicz-Ochocki S.
        • O'Neill W.W.
        • the Primary Angioplasty in Myocardial Infarction Study Group
        A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction.
        N Engl J Med. 1993; 328: 673-679
        • Zijlstra F.
        • de Boer M.J.
        • Hoorntje J.C.
        • Reiffers S.
        • Reiber J.H.
        • Suryapranata H.
        A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.
        N Engl J Med. 1993; 328: 680-684
        • Gibbons R.J.
        • Holmes D.R.
        • Reeder G.S.
        • Bailey K.R.
        • Hopfenspirger M.R.
        • Gersh B.J.
        Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups.
        N Engl J Med. 1993; 328: 685-691
        • Armstrong P.W.
        • Westerhout C.M.
        • Welsh R.C.
        Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction.
        Circulation. 2009; 119: 1293-1303
        • Gershlick A.H.
        • Goldstein P.
        • Wilcox R.
        • Danays T.
        • Lambert Y.
        • Sulimov V.
        • Rosell Ortiz F.
        • Ostojic M.
        • Welsh R.C.
        • Carvalho A.C.
        • Nanas J.
        • Arntz H.-R.
        • Halvorsen S.
        • Huber K.
        • Grajek S.
        • Fresco C.
        • Bluhmki E.
        • Regelin A.
        • Vandenberghe K.
        • Bogaerts K.
        • Van de Werf F.
        • for the STREAM Investigative Team
        Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
        N Engl J Med. 2013; 368: 1379-1387
        • Di Mario C.
        • Dudek D.
        • Piscione F.
        • Mielecki W.
        • Savonitto S.
        • Murena E.
        • Dimopoulos K.
        • Manari A.
        • Gaspardone A.
        • Ochala A.
        • Zmudka K.
        • Bolognese L.
        • Steg P.G.
        • Flather M.
        • on behalf of the CARESS-in-AMI Investigators
        Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
        Lancet. 2008; 371: 559-568